Physicians' Preferencesfor Radioiodine Treatment of Differentiated Thyroid Cancer in Brazil: an Observational Study

Overview

Journal Arch Endocrinol Metab

Specialty Endocrinology

Date 2024 Oct 18

PMID 39420903

Authors

Rosalia do Prado Padovani

Isabella Fagian Pansani

Marilia Martins Silveira Marone

Fernanda Vaisman

Ana Luiza Silva Maia

Jose Miguel Silva Dora

Helton Estrela Ramos

Ana Amelia Fialho de Oliveira Hoff

George Barberio Coura

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this observational, cross-sectional study was to investigate physicians' preferences for radioiodine (RAI) treatment in patients with differentiated thyroid cancer (DTC) in Brazil and the factors influencing RAI indications.

Materials And Methods: A survey was distributed to physicians potentially involved in DTC care in Brazil to understand the factors influencing RAI indications. The survey collected information on the profiles of the physicians, along with the characteristics of their workplaces and their preferences regarding RAI indications in three hypothetical clinical cases. Cases 1, 2, and 3 described the cases of patients with DTC and variations to the case that included different scenarios to assess how the respondents would change their RAI recommendations. The analysis included the RAI indications across different medical specialties.

Results: A total of 175 physicians answered the survey. There was considerable variability in RAI recommendations in all three cases. The training background influenced the respondents' preferences for RAI indications and their approaches to preparing patients for RAI treatment.

Conclusion: The findings of this study reaffirm the need for a Brazilian consensus among physicians across multiple specialties to help guide health care professionals treating patients with DTC in Brazil.

References

Tala H, Robbins R, Fagin J, Larson S, Tuttle R . Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH. J Clin Endocrinol Metab. 2011; 96(7):2105-11. PMC: 7372579. DOI: 10.1210/jc.2011-0305. View

Tuttle R, Lopez N, Leboeuf R, Minkowitz S, Grewal R, Brokhin M . Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid. 2010; 20(3):257-63. DOI: 10.1089/thy.2009.0401. View

Mazzaferri E, Young R, OERTEL J, KEMMERER W, Page C . Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine (Baltimore). 1977; 56(3):171-96. View

Webb R, Howard R, Stojadinovic A, Gaitonde D, Wallace M, Ahmed J . The utility of serum thyroglobulin measurement at the time of remnant ablation for predicting disease-free status in patients with differentiated thyroid cancer: a meta-analysis involving 3947 patients. J Clin Endocrinol Metab. 2012; 97(8):2754-63. DOI: 10.1210/jc.2012-1533. View

Robenshtok E, Tuttle R . Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer. Indian J Surg Oncol. 2013; 3(3):182-9. PMC: 3444583. DOI: 10.1007/s13193-011-0115-1. View

Arjani S, Quinn P, Chokshi R . Preablation Diagnostic Whole-Body Scan vs Empiric Radioactive Iodine Ablation in Differentiated Thyroid Cancer: Cost-effectiveness Analysis. Otolaryngol Head Neck Surg. 2020; 164(6):1172-1178. DOI: 10.1177/0194599820966982. View

Cobin R, Gharib H, Bergman D, Clark O, Cooper D, Daniels G . AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American Association of Clinical Endocrinologists. American College of Endocrinology. Endocr Pract. 2001; 7(3):202-20. View

Schwengber W, Mota L, Nava C, Rodrigues J, Zanella A, de Souza Kuchenbecker R . Patterns of radioiodine use for differentiated thyroid carcinoma in Brazil: insights and a call for action from a 20-year database. Arch Endocrinol Metab. 2020; 64(6):824-832. PMC: 10528611. DOI: 10.20945/2359-3997000000302. View

Vallejo J, Muros M . Cost-effectiveness of using recombinant human thyroid-stimulating hormone before radioiodine ablation for thyroid cancer treatment in Spanish hospitals. Rev Esp Med Nucl Imagen Mol. 2017; 36(6):362-370. DOI: 10.1016/j.remn.2017.04.005. View

10.

Janovsky C, Bittencourt M, Pires de Novais M, Maciel R, Biscolla R, Zucchi P . Thyroid cancer burden and economic impact on the Brazilian public health system. Arch Endocrinol Metab. 2018; 62(5):537-544. PMC: 10118657. DOI: 10.20945/2359-3997000000074. View

11.

Pacini F, Fuhrer D, Elisei R, Handkiewicz-Junak D, Leboulleux S, Luster M . 2022 ETA Consensus Statement: What are the indications for post-surgical radioiodine therapy in differentiated thyroid cancer?. Eur Thyroid J. 2022; 11(1). PMC: 9142814. DOI: 10.1530/ETJ-21-0046. View

12.

Malandrino P, Latina A, Marescalco S, Spadaro A, Regalbuto C, Fulco R . Risk-adapted management of differentiated thyroid cancer assessed by a sensitive measurement of basal serum thyroglobulin. J Clin Endocrinol Metab. 2011; 96(6):1703-9. DOI: 10.1210/jc.2010-2695. View

13.

Haugen B, Alexander E, Bible K, Doherty G, Mandel S, Nikiforov Y . 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015; 26(1):1-133. PMC: 4739132. DOI: 10.1089/thy.2015.0020. View

14.

Haymart M, Banerjee M, Stewart A, Koenig R, Birkmeyer J, Griggs J . Use of radioactive iodine for thyroid cancer. JAMA. 2011; 306(7):721-8. PMC: 3352591. DOI: 10.1001/jama.2011.1139. View

15.

Sawka A, Rotstein L, Brierley J, Tsang R, Thabane L, Gafni A . Regional differences in opinions on adjuvant radioactive iodine treatment of thyroid carcinoma within Canada and the United States. Thyroid. 2007; 17(12):1235-42. DOI: 10.1089/thy.2007.0077. View

16.

Padovani R, Maciel R, Kasamatsu T, Freitas B, Marone M, Camacho C . Assessment of the Effect of Two Distinct Restricted Iodine Diet Durations on Urinary Iodine Levels (Collected over 24 h or as a Single-Spot Urinary Sample) and Na(+)/I(-) Symporter Expression. Eur Thyroid J. 2015; 4(2):99-105. PMC: 4521067. DOI: 10.1159/000433426. View

17.

Pacini F, Castagna M, Brilli L, Pentheroudakis G . Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012; 23 Suppl 7:vii110-9. DOI: 10.1093/annonc/mds230. View

18.

SEIDLIN S, MARINELLI L, OSHRY E . Radioactive iodine therapy; effect on functioning metastases of adenocarcinoma of the thyroid. J Am Med Assoc. 2010; 132(14):838-47. DOI: 10.1001/jama.1946.02870490016004. View

19.

Klubo-Gwiezdzinska J, Burman K, Van Nostrand D, Mete M, Jonklaas J, Wartofsky L . Radioiodine treatment of metastatic thyroid cancer: relative efficacy and side effect profile of preparation by thyroid hormone withdrawal versus recombinant human thyrotropin. Thyroid. 2012; 22(3):310-7. PMC: 4162434. DOI: 10.1089/thy.2011.0235. View

20.

Pacini F, Ladenson P, Schlumberger M, Driedger A, Luster M, Kloos R . Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab. 2005; 91(3):926-32. DOI: 10.1210/jc.2005-1651. View